{"id":"W2560329402","doi":"10.1200/jco.2011.29.7_suppl.312","title":"Phase III, randomized, placebo-controlled study of everolimus in patients with metastatic renal cell carcinoma (mRCC): Subgroup analysis of patients intolerant of prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Everolimus; Medicine; Sorafenib; Sunitinib; Internal medicine; Placebo; Renal cell carcinoma; Subgroup analysis; Oncology; Tyrosine-kinase inhibitor; Adverse effect; Gastroenterology; Urology; Hepatocellular carcinoma; Confidence interval; Cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002995542,0.001746715,0.004851435,0.0005241025,0.0005412365,0.001193154,0.0008141265,0.0017677,0.004669448],"category_scores_gemma":[0.003368195,0.0007747997,0.004120723,0.0006480038,0.0007942549,0.0009293336,0.0004607051,0.002104915,0.0007101629],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006984081,"about_ca_system_score_gemma":0.001315488,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007336945,"about_ca_topic_score_gemma":0.002429531,"domain_scores_codex":[0.9984679,0.0008773608,0.0001510167,0.0002566568,0.00009417569,0.0001528754],"domain_scores_gemma":[0.9984801,0.0005077436,0.0004187081,0.0001641434,0.0001046931,0.000324521],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9871505,0.001849201,0.001679849,0.0003914219,0.003235457,0.00003682974,0.00003238987,0.0001475749,0.001297209,0.00003509289,0.00027078,0.003873743],"study_design_scores_gemma":[0.9590908,0.03209675,0.004955502,0.00002537099,0.002524262,0.00004789331,0.00002709856,0.000363635,0.000269454,0.000118119,0.0004625637,0.00001847507],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.979507,0.00986746,0.0009876054,0.0006847666,0.0006058841,0.004944921,0.001933188,0.00010345,0.001365712],"genre_scores_gemma":[0.9889024,0.002374723,0.001136177,0.0007855332,0.0004263488,0.003665851,0.001612481,0.00002032253,0.001076118],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004851435,"threshold_uncertainty_score":0.01584208,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04974914551332466,"score_gpt":0.3362646173618153,"score_spread":0.2865154718484906,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}